Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Treatment for rare liver disease increases mortality risk

24.08.2005


Patients with primary biliary cirrhosis who are treated with methotrexate have an increased risk of death, according to a new systematic review of studies.

In five randomized controlled trials involving 457 people, the authors report that for patients treated with methotrexate, as a single therapy or in combination with other drug treatment, pooled data showed a tendency toward an increased risk of death or liver transplantation. The brand names for methotrexate are Rheumatrex and Trexall.

“ We do not advocate the use of methotrexate for patients with primary biliary cirrhosis,” conclude lead investigator Yan Gong, M.D., of Copenhagen University Hospital in Denmark and colleagues.


Their review appears in the latest issue of The Cochrane Library, a publication of the Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

The reviewers highlight the mortality and liver transplantation data from one long-term trial in which 11 of 30 patients in the methotrexate group died or underwent liver transplantation, compared with 7 of 30 patients in the placebo group. Combining data from this and another trial other showed that “…methotrexate had a significantly detrimental effect on mortality.”

Methotrexate works by blocking metabolism of cells and is effective in treating certain diseases characterized by abnormal cell growth, like breast cancer and psoriasis. Methotrexate is also widely used to treat rheumatoid arthritis.

Many drugs have been used to treat primary biliary cirrhosis, with ursodeoxycholic acid (a bile acid) the most frequently used. In contrast to methotrexate, the reviewers note that they saw no “significant effect of ursodeoxycholic acid on mortality or liver transplantation.”

Three of the trials compared the therapeutic use of ursodeoxycholic acid with and without methotrexate. One trial compared methotrexate to colchicine.

Primary biliary cirrhosis is an uncommon liver disease, and its cause is unknown, although it may be an autoimmune disease. Ninety percent of patients are women and most are diagnosed after the age of 40. It can be a precursor to cirrhosis of the liver or liver failure.

Studies over the past 30 years indicate an increasing prevalence of the disease, but little progress has been made in slowing disease progression. Primary biliary cirrhosis has become a frequent cause of liver morbidity, and patients with this condition are increasingly undergoing liver transplantation.

The Cochrane reviewers note that their conclusions could be qualified by the size of the data pool and the mixed quality of the studies involved. “Although the majority of the evidence did not point to a beneficial effect of methotrexate for patients with primary biliary cirrhosis,” they write, “we were not able to exclude the possibility for a beneficial effect in certain patient groups. We advise that any new placebo-controlled trials with methotrexate for patients with primary biliary cirrhosis should monitor harmful effects closely.

Keith Lindor, M.D., professor of medicine at the Mayo Medical School, says, “The most important finding in this review of the research is that methotrexate may indeed be harmful in the treatment of primary biliary cirrhosis. The drug should not be used outside of clinical trials, which will not likely be done with this drug because of the lack of efficacy and potential harm.”

Gong Y, Gluud C. Methotrexate for primary biliary cirrhosis. The Cochrane Database of Systematic Reviews 2005, Issue 3.

Yan Gong | EurekAlert!
Further information:
http://www.cfah.org

More articles from Health and Medicine:

nachricht Study tracks inner workings of the brain with new biosensor
16.08.2018 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Foods of the future
15.08.2018 | Georg-August-Universität Göttingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: It’s All in the Mix: Jülich Researchers are Developing Fast-Charging Solid-State Batteries

There are currently great hopes for solid-state batteries. They contain no liquid parts that could leak or catch fire. For this reason, they do not require cooling and are considered to be much safer, more reliable, and longer lasting than traditional lithium-ion batteries. Jülich scientists have now introduced a new concept that allows currents up to ten times greater during charging and discharging than previously described in the literature. The improvement was achieved by a “clever” choice of materials with a focus on consistently good compatibility. All components were made from phosphate compounds, which are well matched both chemically and mechanically.

The low current is considered one of the biggest hurdles in the development of solid-state batteries. It is the reason why the batteries take a relatively long...

Im Focus: Color effects from transparent 3D-printed nanostructures

New design tool automatically creates nanostructure 3D-print templates for user-given colors
Scientists present work at prestigious SIGGRAPH conference

Most of the objects we see are colored by pigments, but using pigments has disadvantages: such colors can fade, industrial pigments are often toxic, and...

Im Focus: Unraveling the nature of 'whistlers' from space in the lab

A new study sheds light on how ultralow frequency radio waves and plasmas interact

Scientists at the University of California, Los Angeles present new research on a curious cosmic phenomenon known as "whistlers" -- very low frequency packets...

Im Focus: New interactive machine learning tool makes car designs more aerodynamic

Scientists develop first tool to use machine learning methods to compute flow around interactively designable 3D objects. Tool will be presented at this year’s prestigious SIGGRAPH conference.

When engineers or designers want to test the aerodynamic properties of the newly designed shape of a car, airplane, or other object, they would normally model...

Im Focus: Robots as 'pump attendants': TU Graz develops robot-controlled rapid charging system for e-vehicles

Researchers from TU Graz and their industry partners have unveiled a world first: the prototype of a robot-controlled, high-speed combined charging system (CCS) for electric vehicles that enables series charging of cars in various parking positions.

Global demand for electric vehicles is forecast to rise sharply: by 2025, the number of new vehicle registrations is expected to reach 25 million per year....

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

LaserForum 2018 deals with 3D production of components

17.08.2018 | Event News

Within reach of the Universe

08.08.2018 | Event News

A journey through the history of microscopy – new exhibition opens at the MDC

27.07.2018 | Event News

 
Latest News

Quantum bugs, meet your new swatter

20.08.2018 | Information Technology

A novel synthetic antibody enables conditional “protein knockdown” in vertebrates

20.08.2018 | Life Sciences

Metamolds: Molding a mold

20.08.2018 | Information Technology

VideoLinks
Science & Research
Overview of more VideoLinks >>>